Bio-Techne Corporation (BVMF:T1CH34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 57.37B +34.0% |
| Revenue (ttm) | 6.32B +0.2% |
| Net Income | 571.23M -16.8% |
| EPS | 3.62 -16.3% |
| Shares Out | n/a |
| PE Ratio | 100.43 |
| Forward PE | 35.58 |
| Dividend | 0.04 (0.31%) |
| Ex-Dividend Date | May 15, 2026 |
| Volume | 1 |
| Open | 12.43 |
| Previous Close | 12.30 |
| Day's Range | 12.43 - 12.43 |
| 52-Week Range | 7.34 - 12.57 |
| Beta | 1.28 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 12, 2026 |
About Bio-Techne
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue cultur... [Read more]
Financial Performance
In fiscal year 2025, Bio-Techne's revenue was $1.22 billion, an increase of 5.23% compared to the previous year's $1.16 billion. Earnings were $73.36 million, a decrease of -56.35%.
Financial numbers in USD Financial StatementsNews
Bio-Techne Proxy statement: Proxy filing
Bio-Techne filed a proxy statement on August 10, 2026, providing details for shareholder voting and corporate governance matters.
Bio-Techne Proxy statement: Proxy filing
Bio-Techne filed a proxy statement on July 9, 2026, providing details for shareholder voting and corporate governance matters.
Bio-Techne downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital analyst Dan Leonard downgraded Bio-Techne (TECH) to Sector Perform from Outperform with a price target of $73, up from $62, citing the view that Merck KGaA (MKGAY) will…
Bio-Techne Launches Expanded R&D Systems AI-Engineered Designer Protein Portfolio
Advancing Scalable Reproducible Cell Therapy and Advanced Cell Culture Workflows New heat-stable and hyperactive proteins across the fibroblast growth factor and interleukin cytokine families expand t...
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: LCI Industries (NYSE – LCII), Iridium Communications Inc. (Nasdaq – IRDM), Bio-Techne Corporation (Nasdaq – TECH), Arcosa, Inc. (NYSE – ACA)
BALA CYNWYD, Pa., July 06, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (j...
Bio-Techne downgraded to In Line from Outperform at Evercore ISI
Evercore ISI downgraded Bio-Techne (TECH) to In Line from Outperform with a $73 price target after the company agreed to be acquired by Merck KGaA (MKGAY) for $73 per share…
Bio-Techne downgraded to Hold from Buy at Benchmark
Benchmark analyst Robert Wasserman downgraded Bio-Techne (TECH) to Hold from Buy after the company announced an agreement to be purchased by Merck KGaA (MKGAY) for $73 per share in cash.
Bio-Techne downgraded to Hold from Buy at TD Cowen
TD Cowen downgraded Bio-Techne (TECH) to Hold from Buy with a price target of $73, up from $65, after Merck KGaA (MKGAF) agreed to acquire Bio-Techne. The new price target…
Bio-Techne downgraded to Neutral from Buy at Citi
Citi downgraded Bio-Techne (TECH) to Neutral from Buy with a $73 price target after the company agreed to be acquired for $73 per share by Merck KGaA (MKGAY). Published first…
Bio-Techne downgraded to Equal Weight from Overweight at Stephens
Stephens analyst Steven Etoch downgraded Bio-Techne (TECH) to Equal Weight from Overweight with a price target of $73, up from $68, after the company agreed to be acquired for $73…
Bio-Techne price target raised to $73 from $49 at Baird
Baird analyst Catherine Ramsey Schulte raised the firm’s price target on Bio-Techne (TECH) to $73 from $49 and keeps a Neutral rating on the shares. The firm raised its target…
Bio-Techne downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank downgraded Bio-Techne (TECH) to Hold from Buy with a price target of $73, up from $66, following Merck KGaA’s proposed acquisition at $73 per share. Published first on…
Bio-Techne downgraded to Market Perform from Outperform at William Blair
William Blair analyst Matt Larew downgraded Bio-Techne (TECH) to Market Perform from Outperform and removed shares from the firm’s Conviction List after the company agreed to be acquired for $73…
Bio-Techne downgraded to Market Perform from Outperform at Leerink
Leerink downgraded Bio-Techne (TECH) to Market Perform from Outperform with a $73 price target after Merck KGaA (MKGAF) agreed to acquire Bio-Techne for $73 per share in cash. Published first…
Bio-Techne Proxy statement: Proxy filing
Bio-Techne filed a proxy statement on June 25, 2026, providing details for shareholder voting and corporate governance matters.
Germany's Merck Is Buying Bio-Techne for $11.3 Billion
Bio-Techne stock jumps, with Germany's Merck KGaA buying the company at a 24% premium.
Merck KGaA to acquire Bio-Techne for $73 per share in cash
Merck KGaA (MKGAF) and Bio-Techne (TECH) entered into a definitive agreement pursuant to which Merck KGaA will, subject to customary closing conditions, acquire Bio-Techne for $73 per share in cash,…
Merck KGaA, Darmstadt, Germany, Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences Markets
Purchase price of US$73 per share in cash represents an enterprise value of US$11.3 billion (EUR 9.9 billion) Proposed acquisition expected to be immediately accretive to sales growth and EBITDA pre m...
Germany's Merck to buy Bio-Techne for $73 per share
Merck KGaA has agreed to acquire biotech firm Bio-Techne Corp for $73 per share in cash, the German science and healthcare firm said in a statement on Thursday.
Germany's Merck to Buy Bio-Techne for $11 Billion
Merck KGaA offered $73 a share in cash to buy Bio-Techne, representing a 24% premium to the U.S. lab-tools supplier's closing price Wednesday.
Bio-Techne named a best smid-cap idea at TD Cowen
TD Cowen analyst Kyle Boucher names Bio-Techne (TECH) a best smid-cap idea in 2026 while keeping a Buy rating on the shares with a $65 price target TD views the…
Bio-Techne initiated with a Neutral at Piper Sandler
Piper Sandler initiated coverage of Bio-Techne (TECH) with a Neutral rating and $65 price target The firm launched coverage of the life science tools sector with a “feet in the…
Bio‑Techne and Refeyn Close Critical Gap in Bispecific Antibody and Biosimilar Characterization
New integrated workflow combines icIEF fractionation and mass photometry Enables direct characterization of aggregation and size within icIEF-resolved charge variants Four-hour workflow reduces develo...